Drugs / AML
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05385770 Comparator | Jul 2022 → Jul 2024 | essential hypertension | Celltrion | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AML | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05385770 ↗ |
| Route | Oral | “tablet, single dose, QD, oral administration” NCT05385770 ↗ |